CureVac (CVAC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CureVac’s partner GSK has reported positive Phase 2 results from their seasonal influenza mRNA vaccine program, demonstrating strong immune responses and an acceptable safety profile. The vaccine, utilizing CureVac’s second-generation mRNA technology, is slated for Phase 3 trials, marking a significant milestone for CureVac. These developments could potentially enhance CureVac’s market position and offer new solutions for influenza prevention.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.